Objective: To compare tolerance of first-line chemotherapy with cisplatin-cyclophosphamide (PC) and cisplatin- paclitaxel (TP) in patients with ovarian cancer stage IIIC. Material and methods: A retrospective review of clinical course in 145 patients treated in Dept. of Gynecology at Medical University of Gdańsk was performed. All patients underwent primary surgery and received adjuvant chemotherapy with six cycles of cisplatin (75 mg/m²) and cyclophosphamide (750 mg/m²) with 21-day intervals – 83 women, and six cycles of cisplatin (75 mg/m²) and paclitaxel (135 mg/m², 24-hour infusion period) at 21-day intervals – 62 women (1999-2001). Toxicity was reviewed and compared in accordance to Common Toxicity Criteria and World Health Organization toxicity scale. Results: Neutropenia, anemia, thrombocytopenia and gastrointestinal toxicity were similar in the two regiment of chemotherapy. Grade 3 and 4 anemia and grade 2 and 3 fatigue were more common in TP group. The peripheral neurotoxicity was more common in TP group than PC group (32% vs. 1.2%). Dose reduction or prolongation of treatment occurred in 16% of PC group and 27% of TP group. The treatment was discontinued in 4 cases – one in PC group and three in TP group. There was one death in PC group due to myelosuppression and progression of disease. Conclusion: The TP regiment was associated with higher frequency of anemia and neurotoxicity than PC. Dose reduction and prolongation of treatment interval due to toxicity concerned more often TP combination.